Depression affects millions globally, presenting a significant challenge for effective treatment. Traditional approaches often rely on trial and error to find ...

Current treatment options for progressive MS are limited, with only a few approved therapies, leaving a substantial gap for novel treatments that can restore neuronal function by promoting myelin ...

The medication, which will be rolled out to patients with relapsing-remitting MS, is thought to be the first in Europe to be taken at home on a widespread basis ...

These cells normally attack viruses and bacteria, but in people with MS, they attack the covering around nerves in the brain and spinal cord known as the myelin sheath. Cladribine stops these cells ...

In people with multiple sclerosis (MS), lesions that get slowly bigger over time, potentially due to chronic inflammation, are associated with more myelin loss throughout the brain, a study found.

Normally, the cells of the immune system attack only foreign material and invading organisms. But in GBS, the immune system starts to destroy the myelin sheath that surrounds the axons of many nerve ...

Myelin – produced by Schwann cells in the periphery and oligodendrocytes in the CNS – is defective in diseases such as multiple sclerosis, and many myelin repair strategies aim to mitigate ...

3.2 Research on the pathophysiological mechanism of myelin sheath injury Myelin sheath injury can occur in many central nervous system diseases, such as multiple sclerosis, nerve trauma, infection, ...

MS International PLC along with its subsidiaries is engaged in the design and manufacture of specialist engineering products and the provision of related services. It manufactures defence equipment, ...

Multiple sclerosis (MS) causes a specific type of damage, called demyelination, to the central nervous system, including the spinal cord. MS is a neurological disease. It causes the immune system ...

GB News more than doubled its revenues in the past year to £15.8m but its total losses now top £100m. The broadcaster decreased its annual losses by a fifth in the year to 31 May 2024. It made a ...

The new analysis found benefits such as reductions in iron and increases in myelin in MS patients with PRLs who were treated with Ocrevus. The findings altogether suggest “a potential reduction ...